Motif Bio plc: PDUFA date: Feb 13, 2019 for Antibiotic Iclaprim. Two Phase 3 trials in pts w acute bacterial skin and skin structure infections (ABSSSI) achieved primary and secondary endpoints. Compared to SoC (vancomycin), no observed nephrotox and a fixed dose. Potential other indications include HABP/VABP and S. aureus lung infections in CF (orphan).
Website:
Address:
125 Park Avenue
25th Floor
New York, NY 10017
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.